Genmab A/S (NASDAQ:GMAB) Earns “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Genmab A/S (NASDAQ:GMABFree Report) in a report published on Thursday, Benzinga reports. They currently have a $50.00 price target on the stock.

GMAB has been the topic of a number of other reports. BMO Capital Markets upgraded Genmab A/S from a market perform rating to an outperform rating and lifted their price target for the company from $46.00 to $48.00 in a research note on Friday, February 23rd. Truist Financial boosted their target price on Genmab A/S from $50.00 to $53.00 and gave the stock a buy rating in a research report on Tuesday, June 4th. Finally, Morgan Stanley reiterated an underweight rating on shares of Genmab A/S in a research report on Tuesday, March 26th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of Hold and a consensus target price of $49.25.

Check Out Our Latest Stock Report on Genmab A/S

Genmab A/S Stock Up 0.6 %

GMAB opened at $26.03 on Thursday. The firm has a market cap of $17.21 billion, a price-to-earnings ratio of 21.69, a price-to-earnings-growth ratio of 0.94 and a beta of 0.99. Genmab A/S has a 52 week low of $25.38 and a 52 week high of $42.72. The business’s 50 day moving average is $28.29 and its two-hundred day moving average is $29.32.

Genmab A/S (NASDAQ:GMABGet Free Report) last released its earnings results on Thursday, May 2nd. The company reported $0.16 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.16. The business had revenue of $603.30 million for the quarter, compared to analyst estimates of $594.23 million. Genmab A/S had a return on equity of 18.90% and a net margin of 30.74%. Equities analysts expect that Genmab A/S will post 1.11 EPS for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

Several institutional investors have recently added to or reduced their stakes in the business. Capital International Investors increased its stake in Genmab A/S by 7.8% in the first quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock valued at $130,805,000 after purchasing an additional 315,355 shares during the last quarter. Harding Loevner LP grew its stake in shares of Genmab A/S by 2.7% in the fourth quarter. Harding Loevner LP now owns 3,289,895 shares of the company’s stock valued at $97,569,000 after buying an additional 85,665 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Genmab A/S by 0.3% in the third quarter. Wellington Management Group LLP now owns 2,425,381 shares of the company’s stock valued at $85,543,000 after purchasing an additional 8,244 shares during the last quarter. First Trust Advisors LP boosted its holdings in Genmab A/S by 16.0% in the fourth quarter. First Trust Advisors LP now owns 1,270,095 shares of the company’s stock valued at $40,440,000 after purchasing an additional 175,292 shares during the last quarter. Finally, Envestnet Asset Management Inc. boosted its holdings in Genmab A/S by 93.6% in the third quarter. Envestnet Asset Management Inc. now owns 946,880 shares of the company’s stock valued at $33,396,000 after purchasing an additional 457,772 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

(Get Free Report)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

See Also

Analyst Recommendations for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.